

Pre-analytical considerations

Successful biomarker profiling from cell-free DNA

Free DNA analysis



Cell-free DNA as a biomarker

Cell-free DNA (cfDNA) that has been shed into the bloodstream or body fluids of healthy or disease-affected individuals is an important analyte in liquid biopsy. These circulating DNA fragments can reveal various alterations such as single nucleotide variants, insertions and deletions and larger chromosomal abnormalities, including copy number variations and translocations, all of which have potential use as biomarkers. It is also possible to assess cfDNA for additional information, including structural variants or modifications, such as DNA methylation.

cfDNA holds great promise to improve clinical practice in several ways:


- By advancing basic disease research and improving our understanding of cfDNA release mechanisms and tissues of origin
- As a companion diagnostic for identifying cancer treatment options through analysis of a defined set of mutations or chromosomal aberrations
- For early disease detection in cancer, the identification of the tissue of origin, therapy monitoring and the assessment of emerging resistance or minimal residual disease monitoring
- For non-invasive prenatal testing (NIPT), enabling the detection of fetal chromosomal abnormalities by analyzing fetal DNA in maternal blood
- As a surrogate marker for post-transplant monitoring

These technical guidelines compile the best practice recommendations and advice of QIAGEN's expert scientists to support the standardization of methods for pre-analytical cfDNA sample collection and preparation.

Biology of cfDNA

In healthy individuals, most cfDNA comes from cells of hematopoietic origin (1), primarily through the shedding of DNA during apoptosis. cfDNA of apoptotic origin typically circulates in fragments ranging from 120–220 base pairs (bp), with a predominant fragment size of around 166–170 bp. This corresponds to the length of DNA that can wrap around a nucleosome (147 bp), plus an additional stretch of DNA to link two nucleosome cores. Apoptosis also can produce longer cfDNA fragments that correspond to di-, tri- or poly-nucleosomes. (2) In addition to apoptosis, cfDNA can be generated through the release of genomic or mitochondrial DNA from any cell type via various mechanisms, including necrosis, active secretion, pyroptosis, autophagy, mitotic catastrophes and NETosis.

The half-life of cfDNA in blood ranges from 15 minutes to 2.5 hours (3), and when it originates from tumor cells, it is referred to as circulating tumor DNA (ctDNA).



cfDNA typically circulates in fragments that range from 120–220 base pairs, with a predominant fragment size of 170 base pairs.

Challenges in cfDNA analysis

The molecular analysis of cfDNA in biofluid samples is complicated by a variety of challenges. First, the analyte is only available in very low and highly variable concentrations, ranging from 1–50 ng/ml in healthy individuals. cfDNA is also highly fragmented and often degraded, affecting downstream molecular

analyses. Furthermore, the target cfDNA molecules for analysis are typically diluted by a higher-abundance background of wild-type or maternal cfDNA and genomic DNA, which can cause misleading results.

The potential for experimental bias through contamination with cellular DNA or substances that inhibit downstream analyses is high, so it is important to minimize this risk. During storage and transport of blood samples, the cells can lyse and release DNA, making it appear that the sample has a higher level of cfDNA than it actually does. The type of anticoagulant and crosslinking reagents in blood collection tubes can impact the quality of cfDNA and the end results (4).

Pre-analytical handling

Various biofluids, including blood serum or plasma and urine, can be used for cfDNA analysis. The choice of sample type depends on the research objective and disease context. Analysis of cfDNA in serum and plasma samples is important to many research applications, including the evaluation of the fetal DNA fraction in maternal blood or the examination of circulating tumor DNA.

Blood serum and plasma

Avoiding cellular DNA contamination

Obtaining accurate results requires appropriate collection and isolation methods that ensure preservation of the sample's actual cfDNA profile. Since cfDNA is only present in blood in low amounts, its level can change dramatically if it becomes diluted with genomic DNA from apoptotic or lysed cells from improper handling. Therefore, measures should be taken to prevent lysis

Five key pitfalls to avoid in cfDNA purification:



Using the wrong sample collection tube



Inadequate storage or transportation concept



Suboptimal centrifugation parameters



Cumbersome or inappropriate cfDNA purification method



Suboptimal methods for quality control or yield quantification


of cells in all steps, from the collection of whole blood to the preparation of serum and plasma. Failure to do so may prevent the subsequent detection of low-abundance cfDNA. Cellular DNA contamination will influence all quantifications of cfDNA yield, except for capillary electrophoresis analysis and similar methods that assess DNA fragment sizes. Cellular contamination can be indirectly quantified by quantitative PCR using both a short and a long target amplicon, where the long assay will only detect cellular DNA (5).

Serum or plasma – which is preferred?

Both serum and plasma samples have been used successfully for biomarker discovery. However, with some serum preparation tubes, a significant contamination of the cfDNA fraction with genomic DNA can occur. Therefore, plasma is the preferred sample type for cfDNA analysis, and most cfDNA studies to date have also been carried out with plasma samples (6).

Collection and stabilization

The use of dedicated, high-quality blood collection tubes minimizes negative impacts on downstream experiments. At QIAGEN, we recommend the PAXgene® Blood ccfDNA Tubes, which stabilize cfDNA in whole blood samples and reduce hemolysis and variability from different shipping or storage conditions (Figures 1–2). The PAXgene Blood ccfDNA Tubes are compatible with our offering of cfDNA purification kits to enable a seamless and standardized pre-analytical workflow.



Sample storage and transportation

Blood samples should be kept within the optimal temperature range from the time of collection through to cfDNA purification. However, temperature control throughout transport is often not possible, and fluctuations can occur, even with the use of cooling packs. When using PAXgene Blood ccfDNA Tubes, blood samples can be stored for up to 10 days at temperatures up to 25°C, 7 days at temperatures up to 30°C or 3 days at temperatures up to 37°C. Do not store blood-filled tubes below 2°C.

Figure 1. PAXgene Blood ccfDNA stabilization minimizes hemolysis compared to alternative solutions. Whole blood from 20 subjects was collected into PAXgene Blood ccfDNA Tubes, EDTA tubes and blood collection tubes designed for ccfDNA stabilization from two other suppliers. Plasma was separated directly after blood draw and after storage at room temperature (15–25°C). An increase in sample hemolysis during sample storage at room temperature was minimized in PAXgene Blood ccfDNA Tubes compared to the other blood collection tubes.




Figure 2. PAXgene Blood ccfDNA stabilization reagent helps prevent release of gDNA into plasma and leaves cfDNA chemically unmodified. Whole blood was stored in EDTA tubes, PAXgene Blood ccfDNA Tubes or tubes from supplier S. cfDNA was extracted from the plasma immediately following blood collection (t0) or after 6 days storage (t6) at room temperature. Plasma from EDTA tubes showed an increase in apoptotic gDNA fragments. Plasma from supplier S showed a broadening and shifting of the main cfDNA peak towards larger fragments, indicating DNA modifications. Plasma from PAXgene Blood ccfDNA Tubes showed a cfDNA profile comparable to day 0.

Sample handling and pretreatment

It is important to handle all samples consistently to avoid introducing any technical variation. The blood draw is a critical first step in plasma preparation, and hemolysis can even occur at the time of phlebotomy. Therefore, blood should only be collected by those highly experienced in venipuncture and according to a standardized procedure. Where possible, samples should also be collected at the same time.

To achieve optimal results from archived samples, care should be taken to select only samples that were collected and processed according to the same protocol. For multi-center studies, bear in mind that different institutions may use different equipment and procedures for sample collection. It is important that the sampling method is consistent throughout the study to minimize any pre-analytical variables.

Plasma preparation

Whole blood should be processed immediately after collection into either serum or plasma. If the whole blood is not centrifuged immediately following collection (or after the clotting time, in the case of serum), the

samples should be stored at 2–8°C for no longer than 4 hours. Prolonged storage may result in lysis of thrombocytes and contamination of the cfDNA profile.

Standard plasma preparation generates three fractions: red blood cells, an intermediate buffy coat layer containing white blood cells, and plasma. The optimal centrifugation speed, time and temperature depend on the particular blood collection tube used. A second high-speed centrifugation step is recommended to reduce cellular contamination (7). Our recommended plasma pre-processing workflow is summarized in Figure 3. The second centrifugation step can be performed at 3000 x g for 15–20 minutes, which is generally sufficient to remove residual cells, platelets, apoptotic bodies and other cell fragments. The centrifugation step can also be performed at 10,000–16,000 x g to remove larger extracellular vesicles (sometimes referred to as microvesicles or microparticles) in the 200–500 nm size range, as they may also contain cfDNA.






Figure 3. Plasma preparation for cfDNA analysis.

Screening for hemolysis

A quick and low-cost method to screen serum and plasma samples for hemolysis is to carry out spectrophotometric measurements of oxyhemoglobin absorbance at 414 nm. Usually, an optical density scan is performed from around 200 to 700 nm, and the presence of distinct absorbance peaks at 414 nm can be used to disqualify samples affected by hemolysis from further analysis.

Our recommendations for blood plasma or serum samples:

- ✓ Only use blood that has been collected by highly trained staff
- ✓ Use appropriate blood collection tubes, such as PAXgene Blood ccfDNA Tubes
- ✓ Minimize the time between blood draw and serum or plasma generation
- ✓ Keep sampling methods consistent for multi-center studies or when using archived samples
- ✓ Maintain proper and consistent shipping and storage conditions
- ✓ Screen for hemolysis

Urine

Urine is an interesting sample material for cfDNA analysis. In contrast to blood plasma, the sample volume is not usually limiting, and collection is simple and non-invasive. Larger volumes of urine can be used for cfDNA extraction to increase sensitivity of the downstream assays. But, keep in mind that urine has the risk of containing concentrated metabolites that could interfere with PCR- or NGS-based analysis.

Urine sample pre-processing for cfDNA analysis

When collecting urine from animals, such as for pre-clinical studies, special consideration should be given to possible sources of contamination and variation due to sample collection procedures. We recommend standardizing sample handling and storage protocols.

The number of different cell types present in urine may vary between individuals or disease states, or following certain medical treatments, and this can affect the cfDNA analysis of whole urine samples. Therefore, urine samples should be centrifuged to remove cells and other debris.

The resulting supernatant can be used directly for cfDNA extraction or alternatively, it can be stored at -80°C . It is important to perform the centrifugation step prior to freezing, as freezing the urine sample first will lead to lysis of cells and the release of gDNA upon thawing.

For analysis of cell-free DNA from urine, urine samples should be stabilized using appropriate collection devices immediately after collection to prevent DNase activity and release of gDNA from cells.

In case no stabilizing agent is available, the cells should be centrifuged immediately following sample collection to prevent genomic DNA release. We recommend adding QIAGEN's buffer ATL, which contains SDS, to the saved supernatant at a ratio of 1:10 to eliminate DNase activity. After a second low-speed centrifugation step, the cell-free supernatant can be used for cfDNA extraction.





Figure 4. Urine pre-processing for cfDNA analysis.

cfDNA purification

Silica membrane-based spin columns and magnetic bead technology can both be used for cfDNA purification. Regardless of the method, it is recommended to use a cfDNA purification kit with a lysis step that releases the nucleic acids that are bound to proteins and lipids and contained in vesicles (8). Some purification kits include the option of adding carrier RNA prior to extraction to increase the yield of cfDNA, but carrier RNA may also negatively affect downstream analysis (9).

The input volume can vary from 1 to 10 ml, depending on the target DNA, the application and the sensitivity of the downstream assay. Typically, input volumes of 4 ml are used, which corresponds to the total plasma volume from one blood collection tube.



Typically, 1 ml of plasma from a healthy individual can contain 1–50 ng of cfDNA.

Recommended purification kits

QIAGEN provides a range of cfDNA purification kits that offer fast workflows and unmatched cfDNA concentrations from varying sample inputs for high sensitivity in downstream NGS and PCR analyses.

Comparison of QIAGEN kits for purification of cfDNA.

Product	Input sample	Automatable	Cat. no.
QIAamp® MinElute ccfDNA Mini Kit (50)	1–4 ml serum or plasma	Partially automated on QIAcube® Connect	55204
QIAamp MinElute ccfDNA Midi Kit (50)	4–10 ml serum or plasma	Partially automated on QIAcube Connect	55284
EZ1&2 ccfDNA Kit (48)	1–8 ml serum or plasma	Yes: EZ1 Advanced XL or EZ2 Connect	954854
QIAamp Circulating Nucleic Acid Kit (50)	Up to 5 ml serum or plasma or up to 4 ml urine	Not automated, processed on QIAvac	55114
QIASymphony® PAXgene Blood ccfDNA Kit (192)*†	2.4, 4.0 or 4.8 ml plasma	Yes: QIASymphony SP	768536
QIAamp ccfDNA/RNA Kit (50)	1–4 ml plasma	Partially automated on QIAcube Connect	55184
QIASymphony DSP Circulating DNA Kit (192)*††	2 or 4 ml human plasma or urine	Yes: QIASymphony SP	937556
QIAamp DSP Circulating NA Kit (50)*	Up to 5 ml serum or plasma	No	61504

* Not available in all countries.

† Customized protocols for large volumes available (only for molecular biology applications). Standard protocol for 2.4 or 4.8 ml plasma. Primary tube handling protocols for 2.4 and 4.0 ml plasma allow direct placement of the centrifuged PAXgene Blood ccfDNA Tubes onto the QIASymphony SP instrument. CE-IVD version coming soon.

†† Customized protocols for large volumes available for molecular biology applications.

Automated cfDNA purification

Automated cfDNA purification methods reduce variability and increase throughput while reducing hands-on time. In contrast to basic research applications, automated cfDNA purification is often the preferred choice in translational research and in the diagnostic routine, as it ensures a standardized workflow with a high traceability and LIMS compatibility, operator-independent reliability and optimal use of time and resources.

A fully automated solution also offers the advantages of using a dedicated cfDNA purification kit, including:

- Optimized purification chemistry
- Prefilled reagent cartridges with bar codes for safety and ease of use
- Reduced risk of exposure and sample mix-up
- Highest reproducibility




Figure 5. Overview of QIAGEN’s automated solutions for various sample throughputs and input volumes.



Determining background

When profiling very low-abundance targets such as biofluid cfDNA, it is important to ensure the signals you are measuring are reliably above any background signal. A blank purification, for example, with water added in place of biofluid sample in the cfDNA purification, can be used as a negative control to measure any background signal.

cfDNA storage

Purified cfDNA may be stored at -15 to -30°C or -65 to -90°C in RNase-free water or in manufacturer-supplied elution buffer. Under these conditions, no degradation of DNA is detectable after one year.

cfDNA quality control

The following parameters should be considered when assessing the quality of cfDNA purified from cell-free biofluids:

- The efficiency of the cfDNA purification and the yield
- The size pattern of the extracted cfDNA
- The absence of any inhibitors of downstream enzymatic processes such as PCR or NGS library preparation
- The absence of nucleases
- The presence or absence of gDNA from cellular contamination or hemolysis




Figure 6. cfDNA qualification on the TapeStation system using the Cell-free DNA Screen Tape assay. Blood was collected in EDTA and PAXgene Blood ccfDNA Tubes. Paired tubes were processed directly (T_0) or after storage for 7 days (T_{7d}) at 25°C . cfDNA extraction was performed automated on the QIA Symphony instrument (QS) using tube-specific kits and protocols. (A) Plasma from stored EDTA tubes showed an increase in apoptotic gDNA fragments. Overlay of cfDNA electropherogram profiles from one exemplary donor. Quantification of cfDNA is evaluated by the assay using a pre-set region from 50–700 bp. Indicated are the lower marker, mononucleosomal peak and high molecular weight (HMW) DNA. (B) Detail of indicated region from panel A.

Basic QC for standard samples

The amount of cfDNA that can be purified as well as the amount of residual inhibitors that remain after purification can vary from sample to sample. When analyzing cfDNA from standard human serum or plasma samples, it is recommended to perform quality control assessments on all samples to monitor the purification yield and absence of PCR inhibitors and to identify any potential problems in the sample set prior to qPCR or NGS experiments. For studies involving a very large number of samples, at least a subset of the samples should be quality controlled.

A successful and high-quality urine collection and stabilization can be confirmed by performing a size analysis on the extracted cfDNA profile. cfDNA will be visible at a fragment size of about 200 bp.

cfDNA quantification

Quantitative, real-time PCR using a multi-copy target gene with known and stable copy number per genome (e.g., GAPDH or β -actin) is the most accurate method

Preferred cfDNA quantification methods

- ✓ Real-time qPCR: short amplicon (<100 bp) of housekeeping gene
- ✓ Digital PCR (e.g., QIAcuity®)

for determining the concentration of small amounts of cfDNA (Figure 7). Alternatively, 18S rDNA can be used as a target (10). Spectrophotometric quantification (e.g., Nanodrop®) is not recommended, because the amount of cfDNA present in plasma and urine is usually too low for reliable measurements. Fluorometric (e.g., Qubit®) or electrophoretic quantification can also be unreliable for cfDNA due to its short nucleic acid fragments. Designated cfDNA assays should be used when using electrophoretic quantification.






Figure 7. Comparison of methods for cfDNA quantification. cfDNA was isolated from six donors using various sample collection tubes and cfDNA extraction methods (manual or automated on QIASymphony). cfDNA quantification using qPCR methods (QIAGEN's Investigator® Quantiplex® Pro Kit or an 18S rDNA qPCR assay) are reliably homogenous in contrast to cfDNA quantification by Qubit, which results in highly variable quantification results.


Multianalyte liquid biopsy

While cfDNA from blood is widely used as an analyte in liquid biopsy research applications, circulating cell-free RNA (ccfRNA), circulating tumor cells (CTCs), exosomes and other extracellular vesicles (EVs) and their contents have also gained relevance for biomarker studies. The ability to combine insights from all of these analytes holds much promise for increasing our understanding of underlying molecular processes. However, challenges in the pre-analytical workflow, such as determining the most suitable blood collection tubes and extraction methods for multimodal analysis must still be overcome.

The ELIMA study (Evaluation of multiple Liquid biopsy analytes In Metastatic breast cancer patients All from one blood sample), approached this challenge and established workflows and compared and analyzed RNA profiles of circulating tumor cells and extracellular vesicles, performed mutational analysis of cfDNA from naïve or CTC-depleted plasma and more. Further information, including science talks, references and a downloadable quick-start workflow poster, is available at: www.qiagen.com/multianalyte-liquid-biopsy.

Multianalyte analysis

CTC nucleic acids




• NGS • qPCR • Pyrosequencing

cfDNA



• NGS • Digital PCR • qPCR

Exosomal RNA



• NGS • qPCR



Download the poster:

Quick-Start Workflow for multianalyte liquid biopsy research

Method standardization

While cfDNA analysis may hold much promise for future clinical applications, standardization of pre-analytical methods is a key prerequisite for its successful use in biobanks, biomarker research and translational research. Various multinational initiatives, including the SPIDIA 4P consortium led by QIAGEN, are driving the development of standardized methods in this field. This involves the creation and transfer of optimal pre-analytical workflows and expert knowledge into CEN technical specifications and ISO standards.

For standardization of the pre-examination process refer to:



ISO 20186-3:2019 – Molecular in vitro diagnostic examinations – Specifications for pre-examination processes for venous whole blood – Part 3: Isolated circulating cell free DNA from plasma

References and further reading

1. Moss, J. et al. (2018) Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. *Nat. Commun.* **9** (1).
2. Bronkhorst, A.J., Ungerer, V., and Holdenrieder, S. (2019) The emerging role of cell-free DNA as a molecular marker for cancer management. *Biomol. Detect. Quantif.* **17**.
3. Stewart, C.M., and Tsui, D.W.Y. (2018) Circulating cell-free DNA for non-invasive cancer management. *Cancer Genet.* **228–229**: 169–179.
4. Voss, T., Ullius, A., Schönborn, M., and Oelmüller, U. (2021) Sensitivity assessment of workflows detecting rare circulating cell-free DNA targets: A study design proposal. *PLoS ONE* **16** (7).
5. Johansson, G. et al. (2019) Considerations and quality controls when analyzing cell-free tumor DNA. *Biomol. Detect. Quantif.* **17**.
6. Keller, L., Belloum, Y., Wikman, H., and Pantel, K. (2021) Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. *Br. J. Cancer* **124** (2).
7. Trigg, R.M., Martinson, L.J., Parpart-Li, S., and Shaw, J.A. (2018) Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature. *Heliyon* **4** (7).
8. Sorber, L. et al. (2017) A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. *J. Mol. Diagnostics* **19** (1).
9. Gyanchandani, R. et al. (2018) Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. *Sci. Rep.* **8** (1).
10. Horlitz, M. et al. (2010) Yields of viral and circulating cell-free nucleic acids using the QIAamp Circulating Nucleic Acid Kit. In *Circulating Nucleic Acids in Plasma and Serum*, Gahan, P.B., Ed., Springer: Dordrecht.
11. Raymond, C.K., Hernandez, J., Karr, R., Hill, K., and Li, M. (2017) Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting. *PLoS One* **12** (4).
12. El-Heliebi, A., and Heitzer, E. (2019) State of the art and future direction for the analysis of cell-free circulating DNA. In *Nucleic Acid Nanotheranostics: Biomedical Applications*.
13. Lampignano, R. et al. (2020) Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre) analytical workflows. *Clin. Chem.* **66** (1).
14. Hofmann, L. et al. (2020) A multi-analyte approach for improved sensitivity of liquid biopsies in prostate cancer. *Cancers (Basel)*. **12** (8).

 Discover more about cfDNA liquid biopsy here: www.qiagen.com/cfDNA

For up-to-date licensing information and product-specific disclaimers, see the respective PreAnalytiX or QIAGEN kit handbook or user manual. PreAnalytiX and QIAGEN kit handbooks and user manuals are available at www.preanalytix.com and www.qiagen.com or can be requested from PreAnalytiX Technical Services.

Trademarks: QIAGEN®, Sample to Insight®, QIAamp®, QIAcube®, QIAcuity®, QIASymphony®, Investigator®, Quantiplex® (QIAGEN Group); PAXgene® (PreAnalytiX GmbH); Bioanalyzer® (Agilent Technologies, Inc.); Qubit® (Molecular Probes, Inc.); NanoDrop® (Thermo Fisher Scientific or its subsidiaries). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law. PROM-19081-002 1125666 08/2021 © 2021 QIAGEN, all rights reserved.

Ordering www.qiagen.com/shop | Technical Support support.qiagen.com | Website www.qiagen.com